Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR)
Open Access
- 15 October 1996
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 24 (20) , 4102-4103
- https://doi.org/10.1093/nar/24.20.4102
Abstract
The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences. Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.Keywords
This publication has 7 references indexed in Scilit:
- Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance [see comments]Blood, 1995
- Gene expression analysis by a competitive and differential PCR with antisense competitors.1994
- Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.1993
- Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapseBritish Journal of Haematology, 1993
- Competitive PCRNature, 1992
- Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of β-interleron gene in chronic myelogeneous leukemiaNucleic Acids Research, 1990
- Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression.Proceedings of the National Academy of Sciences, 1988